NASDAQ · Biotechnology
TARA (TARA) Stock
$3.92
-2.73%
NASDAQ: TARA
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
What Makes Protara Therapeutics (TARA) a New Buy Stock
Zacks · Jul 21, 2026
Protara Therapeutics CMO Leonardo Viana Nicacio Resigns
MT Newswires · Jun 30, 2026
Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight
PR Newswire · Jun 23, 2026
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
Motley Fool · May 31, 2026
Oppenheimer Adjusts Protara Therapeutics PT to $28 From $25, Maintains Outperform Rating
MT Newswires · May 20, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held2.42%
Institutions Held81.11%
Institutions Float Held83.13%
Peer Comparison
About TARA
TARA is led by CEO Jesse Shefferman, employs 28 people, headquartered in US, publicly traded since 2014.
TARA stock trades at $3.92 with a market capitalization of $220.32M. The stock is valued at a price-to-earnings (P/E) ratio of -3.55, price-to-book of 0.94, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.77 and $7.82, and currently trades 49.9% below its 52-week high.
On profitability, TARA generates a return on equity (ROE) of -29.08%, return on capital employed of -33.16%, an operating margin of 0.00%, a net profit margin of 0.00%.